BioArctic's Upcoming Third Quarter Report Presentation
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) is set to release its third quarter financial report for the period from July to September 2025 on November 13, 2025, at 08:00 a.m. CET. This report will shed light on the company's ongoing innovations in the biopharmaceutical field, particularly in tackling neurodegenerative diseases.
On the same day at 09:30 a.m. CET, BioArctic invites all interested parties including investors, analysts, and members of the media to join an informative audiocast with teleconference conducted in English. During this session, Gunilla Osswald, the CEO, along with Anders Martin-Löf, the CFO, and their colleagues, will discuss the quarterly report's insights and strategic direction, followed by a session for questions and answers.
How to Access the Presentation
To participate in the audiocast, attendees can access the live presentation online. Participants will have the opportunity to submit written questions during the session. Details for joining the webcast will be provided during the presentation.
Webcast Link for Audiocast
For those wishing to attend the webcast, it will be available through BioArctic's website, ensuring a user-friendly experience for all participants.
Teleconference Details
For those who prefer to join via teleconference, registration is required. After signing up, participants will receive specific phone numbers and a unique conference ID to join the call. This format allows for interactive participation, including verbal questions during the session.
Post-Presentation Access and Information
Following the live presentation, a recording of the audiocast will be made available on BioArctic's corporate website, allowing anyone who missed the live event to catch up at their convenience.
Contact Information
For further inquiries regarding the presentation or the company, you can reach out to Oskar Bosson, VP of Communications and Investor Relations, who is available via phone at +46 704 10 71 80.
About BioArctic AB
BioArctic AB is a leading Swedish research-focused biopharmaceutical company dedicated to developing innovative treatments aimed at stopping or slowing the progression of neurodegenerative diseases. The company's flagship product, Leqembi (lecanemab), represents a significant advancement in Alzheimer’s disease treatment, having undergone rigorous development in collaboration with their partner Eisai. Besides Leqembi, BioArctic boasts a diverse research portfolio, including projects targeting conditions such as Parkinson's disease and ALS. The utilization of their proprietary BrainTransporter™ technology underpins many of these projects, facilitating the effective delivery of antibodies across the blood-brain barrier. BioArctic's shares (BIOA B) are listed on the Nasdaq Stockholm Large Cap, illustrating their commitment to transparency and shareholder engagement.
Frequently Asked Questions
When will BioArctic publish its third quarter report?
BioArctic will release its third quarter report on November 13, 2025, at 08:00 a.m. CET.
How can I attend the audiocast for the third quarter report?
Interested participants can join the audiocast on November 13, 2025, at 09:30 a.m. CET through BioArctic's website.
Who will be presenting during the audiocast?
Gunilla Osswald (CEO) and Anders Martin-Löf (CFO) will present at the audiocast, supported by their team.
Will there be a Q&A session during the presentation?
Yes, a question and answer session will follow the presentation, where attendees can ask questions.
Where can I find more information about BioArctic?
Further information about BioArctic and their developments can be accessed on their official website.
